GWP
TGTX icon

Gen-Wealth Partners’s TG Therapeutics TGTX Stock Holding History

Gen-Wealth Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,880
Closed -$104K – 725
2025
Q3 		$104K Hold
2,880
– – 0.04% 319
2025
Q2 		$104K Hold
2,880
– – 0.04% 278
2025
Q1 		$114K Hold
2,880
– – 0.05% 263
2024
Q4 		$86.7K Hold
2,880
– – 0.04% 300
2024
Q3 		$72.4K Buy
+2,880
New +$62.9K 0.03% 348

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Gen-Wealth Partners's TGTX Position: Q4 2025 in Review

Gen-Wealth Partners sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 2,880 shares — an estimated $104K sold.

Gen-Wealth Partners first reported a position in TGTX in Q3 2024 and held it in 5 quarters. The position peaked at $114K in Q1 2025. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Gen-Wealth Partners reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Gen-Wealth Partners sold 2,880 TG Therapeutics shares in Q4 2025, an estimated $104K.
  • Gen-Wealth Partners first reported a position in TG Therapeutics in Q3 2024 and held it in 5 quarters.
  • Gen-Wealth Partners's TG Therapeutics position peaked at $114K in Q1 2025.
  • 351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Gen-Wealth Partners's 13F filing for Q4 2025, filed 13 Feb 2026.